Francisco O. García-Pérez, Department of Nuclear Medicine and Molecular Imaging, Instituto Nacional de Cancerología, Mexico City, Mexico
Sevastián Medina-Ornelas, Departamento de Medicina Nuclear e Imagen Molecular, Hospital Ángeles Lindavista, Ciudad de México, México
Prostate cancer is the most common cause of cancer in males worldwide. Currently, imaging in prostate cancer has acquired great importance in staging, re-staging, treatment selection, and recurrence assessment. Molecular imaging with positron-emission tomography has enabled a personalized approach for these purposes. In addition to these clinical needs, there are growing perspectives and a challenge for new molecular imaging techniques, not only to detect metastatic disease, but also to provide relevant information on tumor biology and prognosis, and one of the greatest challenges for non-radioisotope imaging techniques is the ability to detect recurrence in patients with low levels of prostate-specific antigen.
Keywords: Radiotracer. Prostate Cancer. Nuclear medicine. PET/CT.
